Evidence map›Paper›PMID 25249691›Full record

ReviewDrug metabolism and disposition: the biological fate of chemicals2014

Role of (drug) transporters in imaging in health and disease.

Bruno Stieger, Jashvant D Unadkat, Bhagwat Prasad, Oliver Langer, Hariprasad Gali

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug metabolism and disposition: the biological fate of chemicals, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Non-invasive molecular imaging of kidney diseases.Nature reviews. Nephrology · 2021
    Review
  3. Article
  4. Review
  5. Drug transporters in the central nervous system.Clinical pharmacokinetics · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Bruno StiegerDepartment of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland (B.S.); Department of Pharmaceutics, University of Washington, Seattle, Washington (J.D.U., B.P.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria and Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (O.L.); and the Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (H.G.) bruno.stieger@uzh.ch.
Jashvant D UnadkatDepartment of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland (B.S.); Department of Pharmaceutics, University of Washington, Seattle, Washington (J.D.U., B.P.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria and Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (O.L.); and the Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (H.G.).
Bhagwat PrasadDepartment of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland (B.S.); Department of Pharmaceutics, University of Washington, Seattle, Washington (J.D.U., B.P.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria and Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (O.L.); and the Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (H.G.).
Oliver LangerDepartment of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland (B.S.); Department of Pharmaceutics, University of Washington, Seattle, Washington (J.D.U., B.P.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria and Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (O.L.); and the Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (H.G.).
Hariprasad GaliDepartment of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland (B.S.); Department of Pharmaceutics, University of Washington, Seattle, Washington (J.D.U., B.P.); Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria and Health and Environment Department, AIT Austrian Institute of Technology GmbH, Seibersdorf, Austria (O.L.); and the Department of Pharmaceutical Sciences, College of Pharmacy, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma (H.G.).
University Hospital of Zurich · CHUniversity of Oklahoma Health Sciences Center · USUniversity of Washington · US

Funding

Understanding Fetal Exposure to Cannabinoids Through In Vitro and In Vivo StudiesP01DA032507 · NIDA · UNIVERSITY OF WASHINGTON · PI UNADKAT, JASHVANT D · 2013 to 2023
$12.4M
Austrian Science Fund FWF P 24894NIDA NIH HHS P01 DA032507NIDA NIH HHS P01DA032507
6 · The paper itself

Abstract

This report is the summary of presentations at the symposium sponsored by the American Society for Pharmacology and Experimental Therapeutics, April 26-30, at Experimental Biology 2014 in San Diego, CA. The presentations focused on the role of transporters in imaging in health and disease and on assessing transporter function in vivo. Imaging is an important diagnostic tool in clinics and is a novel tool for in vivo visualization of transporter function. Many imaging substrates and endogenous markers for organ function are organic anions. In this symposium, the bile salt transporter sodium taurocholate cotransporting polypeptide and the liver organic anion transporting polypeptides (OATPs) as well as the renal organic anion transporters (OATs) were addressed in detail; e.g., OATPs mediate transport of contrast agents used for magnetic resonance imaging of the liver or transport agents used for hepatobiliary scintigraphy, and OATs transport substances used in renography. In addition, the symposium also focused on the multidrug-resistance transporter 1 (MDR1 or P-gp), which is the most important gatekeeper in epithelial or endothelial barriers for preventing entry of potentially harmful substances into organs. Novel substrates suitable for positron emission tomography (PET) allow the study of such transporters at the blood-brain barrier or while they are mediating uptake of drugs into hepatocytes, and, importantly, PET tracers also now allow renography. Finally, quantitative data on transporter expression in human organs allow the development of improved physiologically based pharmacokinetic (PBPK) models for drug disposition. Hence, the combined efforts using novel substrates for in vivo visualization of transporters and quantification of transporters will lead to a deeper understanding of transporter function in disease and allow development of novel PBPK models for disease states.

Indexed as

AnimalsBiological TransportBlood-Brain BarrierHepatocytesHumansMembrane Transport ProteinsPositron-Emission TomographyMembrane Transport Proteins

Identifiers

PMID25249691
PMCPMC5611776
OpenAlexW2046565934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.